Charles M. Baum

Charles M Baum, M.D., Ph.D. has served as a member of the board of directors since April 2021. Dr. Baum has served as the President and Chief Executive Officer and a member of the board of directors of Mirati Therapeutics Inc. (Nasdaq: MRTX) since November 2012. From June 2003 to September 2012, Dr. Baum held positions of increasing responsibility at Pfizer Inc. (NYSE: PFE) as Vice President and Head of Oncology Clinical Development and subsequently as Chief Medical Officer and Senior Vice President of Clinical Research for the Biotherapeutics and Bioinnovation Center within Pfizer's Worldwide Research & Development division. His experience in targeted oncology included the development of Sutent®, Inlyta®, Xalkori® and Ibrance® while at Pifzer. From 2000 to 2003, Dr. Baum was responsible for the development of several oncology compounds (including Temodar®) at Schering-Plough Corporation (acquired by Merck). Dr. Baum's career has included academic and hospital positions at Stanford University and Emory University, as well as positions of increasing responsibility within the pharmaceutical industry at SyStemix, Inc. (acquired by Novartis AG), and G.D. Searle & Com (acquired by Pfizer). In addition to his director role at Mirati, Dr. Baum currently serves as chairman of the board of OncoMyx Therapeutics, member of the board of directors at BCTG Acquisition Corp, as well as a member of the Scientific Advisory Board for ALX Oncology (NASDAQ: ALXO). Dr. Baum previously served on the board of directors of Immunomedics, Inc. from 2019 until its acquisition by Gilead Sciences, Inc. in 2020 and Array BioPharma Inc. from 2014 until its acquisition by Pfizer in July 2019. Dr. Baum received his M.D. and Ph.D. (Immunology) degrees from Washington University School of Medicine in St. Louis, Missouri and completed his post-doctoral training at Stanford University.